Literature DB >> 8245230

Pathological characteristics of mucopolysaccharidosis VI in the rat.

M Yoshida1, H Ikadai, A Maekawa, M Takahashi, S Nagase.   

Abstract

The histological and electron microscopical characteristics of the pathology of rats with arylsulphatase B-deficient mucopolysaccharidosis (mucopolysaccharidosis VI; MPS VI) were investigated. In affected animals, intracytoplasmic vacuoles were prominent in chondrocytes, the macrophage system, cardiac valve fibroblasts, cornea, connective tissues, vascular smooth muscle cells and uterine stromal cells. Tissues containing glucosaminoglycans stored in lysosomes were positive to Mowry's colloidal iron and alcian blue stains. By electron microscopy, the lysosomes were seen to be distended by electron lucent or fine fibrillary storage material, and lysosomal storage was also detected in the endothelial cells of the arteries and cornea. In the central and peripheral nervous system abnormalities were restricted to the connective tissue. Lesions in the affected rats resembled those described in human and feline mucopolysaccharidosis VI. These results indicate that MPS VI of the rat may be a useful animal model for human MPS VI (Maroteaux-Lamy syndrome).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245230     DOI: 10.1016/s0021-9975(08)80258-7

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  8 in total

1.  Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

Authors:  A C Crawley; K H Niedzielski; E L Isaac; R C Davey; S Byers; J J Hopwood
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Cell-surface arylsulfatase A and B on sinusoidal endothelial cells, hepatocytes, and Kupffer cells in mammalian livers.

Authors:  Keiko Mitsunaga-Nakatsubo; Shinichiro Kusunoki; Hayato Kawakami; Koji Akasaka; Yoshihiro Akimoto
Journal:  Med Mol Morphol       Date:  2009-06-18       Impact factor: 2.309

Review 3.  Animal models for mucopolysaccharidosis disorders and their clinical relevance.

Authors:  Mark E Haskins
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

Review 4.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

5.  Structural, compositional, and biomechanical alterations of the lumbar spine in rats with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).

Authors:  Alon Lai; Calogera M Simonaro; Edward H Schuchman; Yi Ge; Damien M Laudier; James C Iatridis
Journal:  J Orthop Res       Date:  2012-11-28       Impact factor: 3.494

Review 6.  Delivering gene therapy for mucopolysaccharide diseases.

Authors:  Shaun R Wood; Brian W Bigger
Journal:  Front Mol Biosci       Date:  2022-09-12

7.  Sensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI).

Authors:  Paola Saccone; Gabriella Cotugno; Fabio Russo; Rosa Mastrogiacomo; Alessandra Tessitore; Alberto Auricchio; Elvira De Leonibus
Journal:  Sci Rep       Date:  2014-01-10       Impact factor: 4.379

Review 8.  Mucopolysaccharidosis Type VI, an Updated Overview of the Disease.

Authors:  Francesca D'Avanzo; Alessandra Zanetti; Concetta De Filippis; Rosella Tomanin
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.